IN2014DN08604A - - Google Patents

Info

Publication number
IN2014DN08604A
IN2014DN08604A IN8604DEN2014A IN2014DN08604A IN 2014DN08604 A IN2014DN08604 A IN 2014DN08604A IN 8604DEN2014 A IN8604DEN2014 A IN 8604DEN2014A IN 2014DN08604 A IN2014DN08604 A IN 2014DN08604A
Authority
IN
India
Prior art keywords
cushing
phenyl
treatment
methods
vior
Prior art date
Application number
Inventor
Gary Hammer
Tom Kerppola
Raili Kerppola
Original Assignee
Univ Michigan
Atterocor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Michigan, Atterocor Inc filed Critical Univ Michigan
Publication of IN2014DN08604A publication Critical patent/IN2014DN08604A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/025—Halogenated hydrocarbons carbocyclic
    • A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids

Abstract

Methods and compositions are provided for treatment of disorders associated with aberrant adrenal cortex cell beha o vior, including (but not limited to) treatment of adrenocortical carcinoma (ACC), Cushing' s syndrome and/or pituitary ACTH excess (Cushing' s Disease). Such methods involve administration of an effective amount N-(2,6-bis(l-methylethyl)phenyl)-N'-((l-(4-(dimethylamino) phenyl)cyclopentyl)-methyl)urea hydrochloride to the patient.
IN8604DEN2014 2012-03-22 2013-03-13 IN2014DN08604A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261614269P 2012-03-22 2012-03-22
PCT/US2013/031068 WO2013142214A1 (en) 2012-03-22 2013-03-13 Compounds and methods for treating aberrant adrenocartical cell disorders

Publications (1)

Publication Number Publication Date
IN2014DN08604A true IN2014DN08604A (en) 2015-05-22

Family

ID=48014328

Family Applications (1)

Application Number Title Priority Date Filing Date
IN8604DEN2014 IN2014DN08604A (en) 2012-03-22 2013-03-13

Country Status (12)

Country Link
US (5) US9107883B2 (en)
EP (1) EP2838523A1 (en)
JP (2) JP6234987B2 (en)
CN (2) CN106236741A (en)
AU (2) AU2013235535B2 (en)
BR (1) BR112014023517B1 (en)
CA (1) CA2867668A1 (en)
HK (1) HK1206607A1 (en)
IN (1) IN2014DN08604A (en)
MX (1) MX355129B (en)
NZ (1) NZ630828A (en)
WO (1) WO2013142214A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX355129B (en) * 2012-03-22 2018-04-06 Millendo Therapeutics Inc Compounds and methods for treating aberrant adrenocartical cell disorders.
US20150087649A1 (en) * 2013-09-26 2015-03-26 Atterocor, Inc. Treating disorders associated with aberrant adrenocortical cell behavior
CA2962597A1 (en) 2014-09-26 2016-03-31 Millendo Therapeutics, Inc. Solid drug form of n-(2,6-bis(1-methylethyl)phenyl)-n'-((1-(4-(dimethylamino)phenyl)cyclopentyl) methyl)urea hydrochloride and compositions, methods and kits related thereto
US20160287565A1 (en) * 2015-04-06 2016-10-06 Millendo Therapeutics, Inc. Combination therapy for treating disorders associated with excess cortisol production
US20180200209A1 (en) * 2015-07-10 2018-07-19 Millendo Therapeutics, Inc. Enhanced bioavailability of n-(2,6-bis(1-methylethyl)phenyl)-n'-((1-(4-(dimethylamino)-phenyl)cyclopentyl)methyl)urea hydrochloride
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
US10231983B1 (en) 2018-08-22 2019-03-19 Corcept Therapeutics, Inc. Use of ACTH in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients
US11202787B2 (en) 2018-07-02 2021-12-21 Corcept Therapeutics, Inc. Use of ACTH in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients
US10780097B2 (en) 2018-07-02 2020-09-22 Corcept Therapeutics, Inc. Use of cortisol in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients
WO2020252054A1 (en) * 2019-06-11 2020-12-17 The Regents Of The University Of Michigan Compositions and methods for treating cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5015644A (en) 1987-06-02 1991-05-14 Warner-Lambert Company Antihyperlipidemic and antiatherosclerotic urea and carbamate compounds
UA97817C2 (en) * 2006-12-06 2012-03-26 Глаксосмиткляйн Ллк Heterocyclic derivatives of 4-(methylsulfonyl)phenyl and use thereof
WO2009067397A2 (en) * 2007-11-19 2009-05-28 Ore Pharmaceuticals Inc. Treatment for solid tumors
MX355129B (en) * 2012-03-22 2018-04-06 Millendo Therapeutics Inc Compounds and methods for treating aberrant adrenocartical cell disorders.

Also Published As

Publication number Publication date
CN106236741A (en) 2016-12-21
AU2013235535A1 (en) 2014-10-09
CA2867668A1 (en) 2013-09-26
AU2017261632A1 (en) 2017-12-07
JP6234987B2 (en) 2017-11-22
HK1206607A1 (en) 2016-01-15
CN104302283B (en) 2016-08-24
US9877937B2 (en) 2018-01-30
BR112014023517B1 (en) 2020-12-01
NZ630828A (en) 2016-10-28
MX2014011188A (en) 2015-03-06
JP6317016B2 (en) 2018-04-25
MX355129B (en) 2018-04-06
AU2013235535B2 (en) 2017-09-21
US20130267550A1 (en) 2013-10-10
US20160008302A1 (en) 2016-01-14
US9107883B2 (en) 2015-08-18
US9446010B2 (en) 2016-09-20
JP2017160275A (en) 2017-09-14
US20220160662A1 (en) 2022-05-26
WO2013142214A1 (en) 2013-09-26
US20180256524A1 (en) 2018-09-13
CN104302283A (en) 2015-01-21
JP2015510933A (en) 2015-04-13
US20160367507A1 (en) 2016-12-22
EP2838523A1 (en) 2015-02-25

Similar Documents

Publication Publication Date Title
IN2014DN08604A (en)
PH12015501595A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
CR20170563A (en) BENZOXACEPIN OXAZOLIDINONE COMPOUNDS AND METHODS OF USE.
PH12015501598A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
IN2014DN09434A (en)
PH12015501600A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MY188450A (en) Spiro-lactam nmda receptor modulators and uses thereof
MX365939B (en) Nuclear transport modulators and uses thereof.
PH12015500940A1 (en) Bruton`s tyrosine kinase inhibitors
BR112014015568A8 (en) phenyl carbamate compounds for use in the prevention or treatment of epilepsy
EA201892657A1 (en) SPYROLACTAM MODULATORS OF THE NMDA-RECEPTOR AND THEIR APPLICATION
BR112014005268A2 (en) starch compounds as modulators of rort t and uses thereof
EA201400161A1 (en) SUBSTITUTED HETEROAROMATIC PYRAZOL-CONTAINING CARBOXAMIDE AND UTERIN DERIVATIVES AS VIANILLOID RECEPTOR LIGANDS
EP2883875A4 (en) N2,n4-bis(4-(piperazine-1-yl)phenyl)pirimidine-2,4-diamine derivative or pharmaceutically acceptable salt thereof, and composition containing same as active ingredient for preventing or treating cancer
EA201990424A1 (en) SPIRALACTAM MODULERS OF NMDA RECEPTOR AND THEIR APPLICATION
EA201990428A1 (en) SPIRALACTAM MODULERS OF NMDA RECEPTOR AND THEIR APPLICATION
MX2014000829A (en) Polyacrylate-based active compound-comprising particles.
BR112014011981A2 (en) pharmaceutical formulations
BR112015010039A2 (en) treatment of cancer with pomalidomide in an individual with renal dysfunction
EA201492097A1 (en) 5-AMINO [1,4] TIAZINS AS BETA SECRETASE INHIBITORS 1
CL2015000056A1 (en) Carbamate / urea derived compounds, histamine h3 receptor inhibitors; preparation procedure; intermediate compound; pharmaceutical composition; pharmaceutical combination; and use in the treatment of narcolepsy.
EP4086249A3 (en) 6-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same
WO2014081714A3 (en) Methods of treating a disease or disorder associated with bruton&#39;s tyrosine kinase
WO2014081709A3 (en) Methods of treating a disease or disorder associated with bruton&#39;s tyrosine kinase
MX2017003916A (en) Solid drug form of n-(2,6-bis(1-methylethyl)phenyl)-n&#39;-((1-(4-(di methylamino)phenyl)cyclopentyl) methyl)urea hydrochloride and compositions, methods and kits related thereto.